Lia D'Ambrosio

TL;DR: An action framework for countries with low tuberculosis (TB) incidence sets out priority interventions required for these countries to progress first towards “pre-elimination” and eventually the elimination of TB as a public health problem.

TL;DR: Findings from a collaborative, individual patient-level meta-analysis of treatment outcomes among patients with multidrug-resistant tuberculosis are reported.

TL;DR: Treatment outcomes were significantly better with use of linezolid, later generation fluoroquinolones, bedaquiline, clofazimine, and carbapenems for treatment of multidrug-resistant tuberculosis, and the need for trials to ascertain the optimal combination and duration of these drugs is emphasised.

TL;DR: The study results suggest an excellent efficacy but also the necessity of caution in the prescription of linezolid, and the proportion of adverse events was significantly higher when the lineZolid daily dosage exceeded 600 mg.

TL;DR: In XDR-TB patients, regimens containing more drugs than those recommended in MDR- TB but given for a similar duration were associated with the highest odds of success, and better quality evidence is needed to optimise regimens.